Amphotericin B overdosage

Amphotericin B
ABELCET^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overdosage

Amphotericin B desoxycholate overdose has been reported to result in cardiorespiratory arrest. Fifteen patients have been reported to have received one or more doses of ABELCET® between 7-13 mg/kg. None of these patients had a serious acute reaction to ABELCET®. If an overdose is suspected, discontinue therapy, monitor the patient’s clinical status, and administer supportive therapy as required. ABELCET® is not hemodialyzable.^[1]

References

↑ “ABELCET (AMPHOTERICIN B, DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL- AND DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-) INJECTION [SIGMA-TAU PHARMACEUTICALS, INC.]”.

Adapted from the FDA Package Insert.

[dailymed.nlm.nih.gov-1] “ABELCET (AMPHOTERICIN B, DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL- AND DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-) INJECTION [SIGMA-TAU PHARMACEUTICALS, INC.]”.

[1]

Amphotericin B overdosage

Overdosage

References

Looking for the patient version?